Orexo

Orexo OCF Margin

The Operating Cash Flow Margin of Orexo (ORX.ST) as of Oct 10, 2026 is 665.38 %. In the previous year, Operating Cash Flow Margin was -5.54 % — a change of -12,105.41% (higher).

OCF Margin

665.38 %

YoY

-12,105.41%

Last updated:

Operating Cash Flow Margin of Orexo is 2025 665.38 % . Operating Cash Flow Margin of Orexo was 2024 -5.54 % . It decreases by -12,105.41% higher compared to the previous year.

The Orexo OCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF Margin
Date
OCF Margin
Jan 1, 2018
30.90 SEK
Jan 1, 2019
33.97 SEK
Jan 1, 2020
2.53 SEK
Jan 1, 2021
-40.53 SEK
Jan 1, 2022
-25.08 SEK
Jan 1, 2023
-14.87 SEK
Jan 1, 2024
-5.54 SEK
Jan 1, 2025
665.38 SEK
The Orexo OCF Margin history
YEAROCF MarginYoY
665.38 %-12,105.41%
-5.54 %-62.73%
-14.87 %-40.71%
-25.08 %-38.11%
-40.53 %-1,700.97%
2.53 %-92.55%
33.97 %+9.93%
30.90 %+35.69%
22.77 %+2.91%
22.13 %-239.32%
-15.88 %-81.41%
-85.44 %—
Access this data via the Eulerpool API

Orexo Stock analysis

What does Orexo do? Orexo AB is a Swedish pharmaceutical company that was founded in 1995 and is headquartered in Uppsala. The company focuses on the development of medications for the treatment of pain and addiction disorders. Business model: Orexo's business model is based on the development of innovative medications and their marketing in the global market. The company specializes in the development of medications based on opioid technology. Divisions: Orexo operates in two main business areas: Pharmaceuticals and digital therapeutics. Pharmaceuticals: In the pharmaceutical division, Orexo is primarily involved in the development of medications used in the treatment of pain and addiction disorders. Some of the best-known medications include: - Zubsolv: a medication for the treatment of opioid addiction - Abstral: a fast-acting pain medication for cancer patients - Edluar: a sleep medication for the treatment of sleep disorders Orexo's pharmaceuticals are distributed in over 60 countries worldwide and have already helped many patients alleviate their symptoms. Digital therapeutics: Orexo has expanded its business model and offers digital therapeutics - apps that contribute to improving the success of pain and addiction disorder treatment. One example is the app "Orexo Digital," which helps patients better monitor their medication and document the progress of their treatment. The app is free and can be downloaded by patients who have been prescribed medications from Orexo. History: Orexo was founded in 1995 by a team of researchers from Uppsala University. The company initially focused on the development of medications for the treatment of inflammatory diseases and allergies. In 2003, the company decided to concentrate on the development of medications in pain and addiction treatment. The first products in this area were the pain medication Abstral and the substitution medication Zubsolv. In the following years, the company grew rapidly and opened additional locations in the United States, United Kingdom, and France. Orexo works closely with key players in the healthcare sector to ensure that its medications are accessible to patients worldwide. Products: Abstral: a medication for the treatment of acute and chronic severe pain. It is taken sublingually and acts quickly. Zubsolv: a medication for the treatment of opioid addiction. It contains the active ingredients buprenorphine and naloxone and can alleviate withdrawal symptoms in opioid addiction. Edluar: a sleep medication for the treatment of sleep disorders. It contains the active ingredient zolpidem and is taken sublingually. Orexo Digital: an app to support patients in the treatment of pain and addiction disorders. It enables the monitoring of treatment progress and provides helpful advice for improving treatment success. Conclusion: Orexo is an innovative pharmaceutical company specializing in the development of medications for the treatment of pain and addiction disorders. The company has made a name for itself with its unique opioid technology and offers successful products such as Abstral and Zubsolv. With its expansion into the field of digital therapeutics, Orexo also demonstrates that it remains at the forefront of technology and innovation. Orexo is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Orexo stock

Operating Cash Flow Margin of Orexo is 665.38 % in 2025.

Operating Cash Flow Margin of Orexo changed from -5.54 % to 665.38 %, representing a -12,105.41% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Margin Orexo since 2006 – with annual values, charts, and detailed analysis.

OCF margin measures the percentage of revenue converted into operating cash flow. It indicates cash generation efficiency from core business operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow Margin's Orexo with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Cash Flow Margin.

Access this data via the Eulerpool API

Margins — Orexo

All Key Metrics — Orexo